Medical Management of Benign Prostatic Hyperplasia
March 2024
in “
Cleveland Clinic journal of medicine
”
Studysummary This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer